Shionogi to License Cefiderocol Antibiotic Drugs to Multiple Countries

Shionogi has entered into an agreement with the Global Antibiotic Research and Development Partnership to license its antibiotic, cefiderocol, to nearly 70 percent of countries worldwide.

The drug is meant to treat serious Gram-negative bacterial infections that could be resistant to other antibiotic treatments.

The licensing agreement makes the drug more accessible in 135 countries, including all low-income countries, most middle-income countries and select high-income countries.

Branded as Fetroja, cefiderocol is FDA-approved for the treatment of complicated urinary tract infections and for bacterial pneumonia caused by susceptible Gram-negative microorganisms.